Fundraising FoxAdvent Life Sciences — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.
BiotechHealthtechCambridge, US
Damia Tormo(President, CEO, Treasurer and Founder)inJoe Suarez(Executive Officer)Maria Nichol(Executive Officer)inRobert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)in
BoardAndre Hoekema(Director)
Board seatRaj ParekhAlan Walts· per SEC Form D
Co-investorsSound BioventuresColumbus Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.